C.R. Jackson
Biotech, healthcare, value, research analyst

Tetraphase Pharmaceuticals: A Small Cap With Big Potential

According to the US Centers for Disease Control and Prevention (NASDAQ:CDC), at least 2 million people in the United States become infected with bacteria that are resistant to antibiotics each year and at least 23,000 people die each year as a direct result of these infections. Many more people die from other conditions that were complicated by an antibiotic-resistant infection.

The rapid rise of multi-drug-resistant bacterial infections is a major global public health concern. Currently approved drugs are becoming increasingly ineffective and there are few new therapeutic agents in clinical development.

Watertown, Massachusetts-based Tetraphase Pharmaceuticals (NASDAQ:TTPH) has the opportunity to meet this umet and urgent medical need.

Would an investment in Tetraphase make a lucrative addition...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details